Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of AVANZ Salsola kali immunotherapy (up-dosing phase)
2013-001728-20Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Sep 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Avanz Salsola kali in allergic rhinoconjunctivitis (ARC), allergic rhinitis (AR) and asthma, sponsored by ALK-Abelló. Primary endpoints: Incidence of adverse reactions to Salsola kali AVANZ immunotherapy and Incidence of systemic reactions according to EAACI classification. Started Sep 2013; status: completed.
02
Drugs
Avanz Salsola kali
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on 2013-001728-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001728-20.